Impact of an inter-professional clinic on pancreatic cancer outcomes: The Princess Margaret Cancer Centre (PM) experience.

Authors

Hamzeh Albaba

Hamzeh Albaba

Princess Margaret Cancer Centre, Toronto, ON, Canada

Hamzeh Albaba , Anna Dodd , Rebecca M. Prince , Kyaw Lwin Aung , David W. Hedley , Steven Gallinger , John Kim , James D. Brierley , Shari Moura , Stephanie Moignard , Adriana Fraser , Shawn Hutchinson , Osvaldo Espin-Garcia , Carolanne Moulton , Alice Chia-chi Wei , Paul David Greig , Ian M McGilvray , Neesha C. Dhani , Elena Elimova , Jennifer J. Knox

Organizations

Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Toronto General Hospital, Toronto, ON, Canada, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada, Toronto General Hospital, University Health Network, Toronto, ON, Canada, University of Toronto, Toronto, ON, Canada, University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

Other

Background: Patients with pancreatic ductal adenocarcinoma (PDAC) have limited treatment options. Management of complex symptoms and psychosocial implications requires an interprofessional approach as prognosis is often measured in months. A multidisciplinary approach has been associated with improvement in clinical outcomes including survival. We aimed to evaluate the impact of an inter-professional approach for PDAC patients at the Wallace McCain Centre for Pancreatic Cancer (WMCPC) at PM on their management and clinical outcomes. Methods: We undertook retrospective review of all patients with PDAC seen at PM two years before (July ‘12 – June ‘14) and two years after (July ‘14 – June ‘16) establishment of the WMCPC. Standard therapies (surgical approach, chemotherapy, radiation therapy) were the same during both time periods. Comparison of overall survival (OS), stage at diagnosis, surgical outcomes, waiting times, and proportion seen by social worker, dietician and clinical nurse specialist (CNS) was explored with descriptive statistic and survival analysis. Results: A total of 993 patients were reviewed; 482 patients pre- and 511 patients post-WMCPC. Age (median 67 yrs), sex (54% men) and stage III/IV (52%) were similar in both groups. There was a trend to improved OS in the post-WMCPC group (9.6 vs. 10.9 m; p = 0.055); multivariable analysis found a significant improvement in OS after adjustment for performance status and stage (p = 0.023; HR 0.84, 95% CI 0.72-0.98). Rate of R0 versus R1/R2 resection for curative surgery (n = 264, 28%) was similar in both groups. Time from referral to first clinic visit significantly decreased from 13.4 to 8.8 days in the post-WMCPC group (p < 0.001) as did time from first clinic appointment to diagnostic biopsy (25.9 vs. 16.9 days, p = 0.022). Patients in the post-WMCPC were more frequently seen by a social worker, dietician or CNS (8% vs. 38%, 9% vs. 35% and 31% vs. 50% respectively, p < 0.001). Conclusions: Establishment of an interprofessional clinic for the treatment of PDAC patients at PM has streamlined diagnosis, aided symptom management and improved overall survival. This has implications for planning care delivery models and proves the value of this intervention.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 444)

DOI

10.1200/JCO.2019.37.4_suppl.444

Abstract #

444

Poster Bd #

P4

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Advanced pancreatic cancer outcomes and the impact of COVID-19 pandemic: The experience of an academic cancer center.

First Author: Christian Adams-Carey

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

New cutoff of CA19-9 values for predicting pancreatic cancer using liquid biopsy.

First Author: Ryuji Hasebe

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

The prognostic value of mutational signatures in pancreatic cancer.

First Author: Nicholas Light